Meet mycoBiologics Ltd. mycoBiologics is developing a new, safer, more effective therapy for hospitalised patients with deadly fungal infections. The TeamDr Fiona Rudkin - PhD in Microbiology and 15 years experience in antibody discovery and preclinical development at Pfizer and the University of Aberdeen. Completed entrepreneurial training at MIT and the Royal Society of Edinburgh Enterprise Fellowship programme.Dr Kayleigh Earle - PhD in Medical Mycology with experience in host-pathogen interactions and immune assays. M.Res. from Universitat Pompeu Fabra, Spain.Dr Satpal Chodha - PhD in Biotechnology. Biochemist and protein-engineering researcher focused on antimicrobial resistance. Previous positions at Sheffield, Imperial College London and Northwestern University (Chicago). ProblemDespite treatment, around half a million people die every year due to a lethal Candida infection. Current treatments are limited by toxicity, drug resistance and a lack of innovation. As such, these are becoming less effective, particularly in hospitalised patients with complex underlying medical conditions.Solution mycoBiologics is developing a new, safer and more effective treatment for deadly Candida infections in hospitalised patients. Our first-in-class, patient-derived monoclonal antibody (mAb) therapy will initially be used alongside current antifungals to enhance their effectiveness in complex patient populations, help mitigate resistance and extend the lifespan of existing therapies.ContactmycoBiologics Ltd websitemycoBiologics Ltd LinkedInFiona Rudkin LinkedIn This article was published on 2025-10-28
